Co-Diagnostics, Inc. (NASDAQ: CODX) entered into a material transfer agreement with ReadyGo Diagnostics Ltd in August 2026 to evaluate the potential compatibility of ReadyGo's sample collection and preparation technologies with Co-Diagnostics' Co-Dx PCR platform, according to a company statement.

ReadyGo develops technologies designed to simplify the front end of diagnostic testing, including tools intended to collect biological samples, lyse cells, stabilize nucleic acids, and prepare samples for downstream molecular analysis.

Under the agreement, ReadyGo will provide sampling materials to Co-Diagnostics for feasibility studies, including compatibility testing with Co-Diagnostics' products. The Co-Dx PCR platform is being developed to deliver real-time PCR testing in decentralized and point-of-care settings through a compact instrument and proprietary test cups.

Co-Diagnostics stated that the evaluation activities are preliminary in nature and that the agreement does not obligate either party to enter into any development, supply, commercialization, or other commercial arrangement. The company noted there is no assurance the evaluation will result in any additional agreement or commercial relationship between the parties.

The Co-Dx PCR platform and its associated tests are subject to review by the U.S. Food and Drug Administration and other applicable regulatory authorities and are not currently available for sale.